AMAG Pharmaceuticals, Inc. has received a key new US patent for ferumoxytol, Patent No. 8,591,864, Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents, expiring in March 2020 from Patent and Trademark Office (USPTO).

This patent is directed to compositions that include the chemical structure and to 500 mg to 600 mg unit doses of ferumoxytol. This patent is listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the United States Food and Drug Administration.

"We are pleased to announce this new patent for ferumoxytol that is especially important for the long-term value of a product that generated 28 percent revenue growth last year in the United States," commented Frank Thomas, chief operating officer of AMAG.

AMAG now has five Orange Book-listed patents for ferumoxytol, with patent protection through March 2020, without patent term extension. AMAG has applied for a patent term extension for an Orange Book-listed ferumoxytol patent, which would lengthen that patent term through June 2023.

AMAG Pharmaceuticals Inc. is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection and MuGard Mucoadhesive Oral Wound Rinse in the United States.